348 related articles for article (PubMed ID: 26598544)
1. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
Dimopoulos MA; Kastritis E; Ghobrial IM
Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
[TBL] [Abstract][Full Text] [Related]
3. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
7. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
Grunenberg A; Buske C
Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
[TBL] [Abstract][Full Text] [Related]
8. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
9. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Dimopoulos MA; Kastritis E; Owen RG; Kyle RA; Landgren O; Morra E; Leleu X; García-Sanz R; Munshi N; Anderson KC; Terpos E; Ghobrial IM; Morel P; Maloney D; Rummel M; Leblond V; Advani RH; Gertz MA; Kyriakou C; Thomas SK; Barlogie B; Gregory SA; Kimby E; Merlini G; Treon SP
Blood; 2014 Aug; 124(9):1404-11. PubMed ID: 25027391
[TBL] [Abstract][Full Text] [Related]
10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
11. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
12. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
13. Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
15. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Furman RR; Luan Y; Bilotti E; Graef T
Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
[No Abstract] [Full Text] [Related]
16. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
17. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
19. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]